米氮平治疗精神分裂症后抑郁的临床研究

The Study of Mirtazapine in the Treatment of Patients with Post-schizophrenic Depression

目的观察米氮平治疗精神分裂症后抑郁患者的疗效及副作用。方法符合《中国精神障碍分类与诊断标准》(CCMD-3)精神分裂症后抑郁的诊断。将病例随机分为米氮平组和氟西汀组,治疗6周,采用汉密尔顿抑郁量表(HAMD)、简明精神病量表(HPKS)、阴性症状量表(SANS)及副反应量表(TESS)评定疗效及药物不良反应。结果米氮平组总有效率85.3%。氟西汀组84.3%。两组均无明显不良反应。结论米氮平治疗精神分裂症后抑郁安全、有效,副反应少。

Objective To observe the efficacy and the side effects of mirtazapine in the treatment of patients with post- schizophrenic depression. Methods Patients according to CCMD--3 criteria of post-schizophrenic depression were randomly assigned to mirtazapine group and fluoxetine group for the treatment of 6 weeks. The efficacy were assessed by HAMD, SPRS and SANS. The side effects were assessed by TESS. Results The overall effective rate was 85.3% in mirtazapine group and 84.3%; in fluoxetine group. Conclusion Mirtazapine is effective and safe drug in the treatment of patients with post-schizopluenic depression.